Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes
Primary Purpose
Diabetes, Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
repaglinide
metformin
glicazide
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes for at least 3 months
- No previous treatment for diabetes
- HbA1c between 7.0-12.0%
- Body Mass Index (BMI) between 19.0-40.0 kg/m2
Exclusion Criteria:
- Type 1 diabetes
- Known unstable/untreated proliferative retinopathy
- Uncontrolled treated/untreated hypertension
- Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures
Sites / Locations
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
- Novo Nordisk Investigational Site
Outcomes
Primary Outcome Measures
HbA1c
Secondary Outcome Measures
Glucose profiles
Quality of life assessment
Treatment satisfaction
Hypoglycaemic events
Adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00568984
Brief Title
Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes
Official Title
Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
November 21, 2002 (Actual)
Primary Completion Date
November 10, 2003 (Actual)
Study Completion Date
November 10, 2003 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of blood glucose control with combination therapy of repaglinide and metformin compared to conventional treatment with a sulphonylurea or metformin in monotherapy in type 2 diabetes
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
324 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
repaglinide
Intervention Type
Drug
Intervention Name(s)
metformin
Intervention Type
Drug
Intervention Name(s)
glicazide
Primary Outcome Measure Information:
Title
HbA1c
Time Frame
after 16 weeks of treatment
Secondary Outcome Measure Information:
Title
Glucose profiles
Title
Quality of life assessment
Title
Treatment satisfaction
Title
Hypoglycaemic events
Title
Adverse events
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes for at least 3 months
No previous treatment for diabetes
HbA1c between 7.0-12.0%
Body Mass Index (BMI) between 19.0-40.0 kg/m2
Exclusion Criteria:
Type 1 diabetes
Known unstable/untreated proliferative retinopathy
Uncontrolled treated/untreated hypertension
Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100034
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100044
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300052
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Cheras
ZIP/Postal Code
56000
Country
Malaysia
Facility Name
Novo Nordisk Investigational Site
City
Ipoh
ZIP/Postal Code
30450
Country
Malaysia
Facility Name
Novo Nordisk Investigational Site
City
Kota Bharu, Kelantan
ZIP/Postal Code
16150
Country
Malaysia
Facility Name
Novo Nordisk Investigational Site
City
Cebu City
ZIP/Postal Code
6000
Country
Philippines
Facility Name
Novo Nordisk Investigational Site
City
Manila
ZIP/Postal Code
1003
Country
Philippines
Facility Name
Novo Nordisk Investigational Site
City
Marikina City
ZIP/Postal Code
1800
Country
Philippines
Facility Name
Novo Nordisk Investigational Site
City
Pampanga
ZIP/Postal Code
2000
Country
Philippines
Facility Name
Novo Nordisk Investigational Site
City
Quezon City
ZIP/Postal Code
1100
Country
Philippines
Facility Name
Novo Nordisk Investigational Site
City
Quezon
ZIP/Postal Code
4301
Country
Philippines
Facility Name
Novo Nordisk Investigational Site
City
Bangkok
ZIP/Postal Code
10300
Country
Thailand
Facility Name
Novo Nordisk Investigational Site
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
12. IPD Sharing Statement
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk
Learn more about this trial
Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes
We'll reach out to this number within 24 hrs